Zevra Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Zevra Therapeutics, Inc. (ZVRA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $240.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- Zevra Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $122.00K.
- Zevra Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $118.00K.
- Zevra Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $0.00.
- Zevra Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $0.00.
- Zevra Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $602.00K, a 9.06% increase from fiscal 2024.
- Zevra Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $552.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $240.00K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $118.00K 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | $602.00K 10-K · filed 2026-03-09 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | ||
| 2024-12-31 | $552.00K 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |